Onxeo is developing innovative oncology drugs based on DNA-targeting and epigenetics. The lead compound, AsiDNA, is a first-in-class DNA break repair inhibitor based on a unique decoy mechanism and currently evaluated in a phase I trial (DRIIV-1) for systemic administration in solid tumors.
Onxeo’s lead asset AsiDNA, a first-in-class DNA break repair inhibitor, is now being tested in the Phase Ib part of the DRIIV-1 trial at the Institut Curie in Paris in patients with advanced solid tumours in combination with chemotherapy. AsiDNA has already generated supportive data from a Phase I trial in melanoma using intratumoural injection, but is now being tested via systemic administration. Onxeo is conducting a broad preclinical programme that explores AsiDNA in various settings and combinations with other drugs. AsiDNA is part of the proprietary, novel platON platform and is based on decoy oligonucleotides. The platON platform belongs to the so-called DNA damage response (DDR) technology, a domain to which recently marketed PARP inhibitors also belong. After receiving $7.5m from the sale of rights to royalties from Beleodaq and a €5.4m equity financing line, cash reach will extend into Q320 past the AsiDNA Phase I results.
The approval of the first PARP inhibitor (olaparib) has kick started the interest of both the scientific community and large pharma in the DNA Damage Response (DDR) field. Few biotechs are already positioned in this emerging field which may be the successor to immuno-oncology.